City Of Hope's Joseph Alvarnas On CAR-T Real-World Use, Reimbursement
City of Hope hematologist/oncologist Joseph Alvarnas shares his perspectives on how CAR-T therapies are requiring new models of health care delivery and engagement with more kinds of stakeholders, during an interview at the recent ASH annual meeting.
You may also be interested in...
T-cell-engaging bispecific antibodies emerged at ASH as viable competitors for autologous T-cell therapies, but while their off-the-shelf availability is intriguing, it may be too early to say if their safety and efficacy beats CAR-Ts.
Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.
As new drugs move into earlier lines of therapy for use in combination and for longer periods, payers are growing more sensitive to myeloma therapies' costs in the US and major ex-US markets.